<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00411177</url>
  </required_header>
  <id_info>
    <org_study_id>Ege0683</org_study_id>
    <nct_id>NCT00411177</nct_id>
  </id_info>
  <brief_title>Comparison of Post-dilution On-line Hemodiafiltration and Hemodialysis</brief_title>
  <official_title>Comparison of Post-dilution On-line Hemodiafiltration and Hemodialysis (TURKISH HDF STUDY)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ercan OK</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fresenius Medical Care North America</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Ege University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to compare high-efficiency post-dilution on-line hemodiafiltration and
      high-flux hemodialysis regarding mortality, hospitalization rate, several clinical and
      laboratory parameters, and required medications.

      The investigators hypothesize that high-efficiency post-dilution on-line hemodiafiltration
      may provide better outcome, less morbidity, higher quality of life, and lesser requirement of
      medications.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The proposed controlled, randomized study aims to compare high-efficiency post-dilution
      on-line hemodiafiltration and high-flux hemodialysis regarding mortality, hospitalization
      rate, several clinical and laboratory parameters, and required medications.

      Seven hundred and eighty HD patients will be taken into the study. The study will last for
      two years with an intermediate analysis at the first year. The patients will be randomly
      placed in two groups:

        1. Post-dilution on-line hemodiafiltration,

        2. High-flux hemodialysis.

      In both groups, FX series high-flux helixone membranes will be used, duration of each session
      240 minutes, and blood flow rates 250-400 ml/min. ONLINEplus integrated Fresenius 4008S
      machines will be used for on-line post-dilution HDF. Substitution volume will be above 15
      liters in hemodiafiltration sessions.

      Echocardiography for determination of left ventricular geometry, pulse wave velocity analysis
      to assess arterial stiffness, evaluation of nutritional and inflammatory state, assessment of
      life quality, depression and cost analysis will be performed.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2007</start_date>
  <completion_date type="Actual">March 2010</completion_date>
  <primary_completion_date type="Actual">January 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>composite of overall mortality and new cardiovascular events to include myocardial infarction, stroke, revascularization, and unstable angina pectoris requiring hospitalization.</measure>
    <time_frame>two years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>cardiovascular mortality</measure>
    <time_frame>two years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hospitalization rate</measure>
    <time_frame>two years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>intradialytic complications including hypotension and cramp</measure>
    <time_frame>two years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>health-related quality of life, depression burden, cognitive function</measure>
    <time_frame>two years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>required medications</measure>
    <time_frame>two years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes in blood pressure, left ventricular geometry, arterial stiffness, post-dialysis body weight, upper mid-arm circumference, hematocrit and related rHu-EPO doses, the levels of phosphorus, albumin, lipid parameters, hsCRP, and Î²-2 microglobulin</measure>
    <time_frame>two years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>postdialysis total body water determined by bioimpedance analysis</measure>
    <time_frame>two years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">782</enrollment>
  <condition>End-Stage Renal Disease</condition>
  <arm_group>
    <arm_group_label>Post-dilution on-line hemodiafiltration</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Post-dilution on-line hemodiafiltration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High-flux hemodialysis</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>High-flux hemodialysis</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>post-dilution on-line hemodiafiltration</intervention_name>
    <description>post-dilution on-line hemodiafiltration, 3 times a week 4 hours</description>
    <arm_group_label>Post-dilution on-line hemodiafiltration</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>high flux hemodialysis</intervention_name>
    <description>High-flux hemodialysis, 3 times a week 4 hours</description>
    <arm_group_label>High-flux hemodialysis</arm_group_label>
    <other_name>High-flux hemodialysis</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  older than 18 years

          -  on maintenance bicarbonate HD scheduled thrice weekly 12 hours/week,achieved mean
             single pool Kt/V above 1.2

          -  willingness to participate in the study with a written informed consent

        Exclusion Criteria:

          -  To be scheduled for living donor renal transplantation

          -  To have serious life-limiting co-morbid situations, namely active malignancy, active
             infection, end-stage cardiac, pulmonary, or hepatic disease

          -  Pregnancy or lactating

          -  Current requirement for HD more than three times per week due to medical comorbidity

          -  GFR greater than 10 ml/min/1.73 m2 as measured by the average of urea and creatinine
             clearances obtained from a urine collection of at least 24 hours

          -  Use of temporary catheter

          -  Insufficient vascular access (blood flow rate lower than 250 ml/min)

          -  Mental incompetence
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ercan Ok, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ege University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ege University School of Medicine</name>
      <address>
        <city>Bornova</city>
        <state>Izmir</state>
        <zip>35100</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FMC Clinics Turkey</name>
      <address>
        <city>Adana</city>
        <zip>01000</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 12, 2006</study_first_submitted>
  <study_first_submitted_qc>December 12, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 13, 2006</study_first_posted>
  <last_update_submitted>September 6, 2013</last_update_submitted>
  <last_update_submitted_qc>September 6, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 9, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Ege University</investigator_affiliation>
    <investigator_full_name>Ercan OK</investigator_full_name>
    <investigator_title>professor</investigator_title>
  </responsible_party>
  <keyword>end-stage renal disease</keyword>
  <keyword>hemodialysis</keyword>
  <keyword>cardiovascular morbidity and mortality</keyword>
  <keyword>high flux dialyser</keyword>
  <keyword>on-line hemodiafiltration</keyword>
  <keyword>arterial stiffness</keyword>
  <keyword>inflammation</keyword>
  <keyword>life quality</keyword>
  <keyword>left ventricular hypertrophy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

